Lannett Company Inc (LCI):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Lannett Company Inc (LCI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10032
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Lannett Company Inc (Lannett) is a pharmaceutical company. It develops, manufactures and distributes generic prescription pharmaceutical products in tablet, capsule and oral liquid forms. The company offers generic pharmaceuticals for medical indications such as antibiotic, cardiovascular, central nervous systems, gallstone, gastrointestinal, glaucoma, gout, migraine, muscle relaxant, obesity, pain management, respiratory, thyroid deficiency and urinary. Lannett also offers laboratory services, product formulation and development services, granulation, blending, encapsulation, compression, coating and packaging solid dosage forms. The company sells its pharmaceutical products across the US to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private-label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations and health maintenance organizations. Lannett is headquartered in Philadelphia, Pennsylvania, the US.

Lannett Company Inc (LCI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lannett Company Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Lannett Company Inc, Medical Devices Deals, 2012 to YTD 2018 11
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Lannett Company Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Lannett Acquires Portfolio of Generic Products from Endo International 13
Lannett to Acquire Estradiol Tablets and Selegiline Hydrochloride Capsules 14
Partnerships 15
Lannett Enters into Distribution Agreement with Aralez Pharma 15
Lannett to Form Partnership with YiChang HEC ChangJiang Pharmaceutical 16
Lannett Enters into Co-Marketing Agreement with Sunshine Lake 17
Panacea Biotec Enters Into R&D Agreement With Kremers Urban For Generic Drugs 18
Licensing Agreements 19
Lannett Amends Licensing Agreement with Andor Pharma 19
Equity Offering 20
Lannett Company Files Registration Statement to Raise Funds through Public Offering of Securities 20
Lannett Completes Public Offering Of Shares For US$76.5 Million 21
Lannett Files Shelf Registration Statement For Public Offering Of Securities For Up To US$64 Million 22
Acquisition 23
Lannett Company Plans to Sell Cody Laboratories 23
Lannett Acquires Kremers Urban Pharma for USD1.23 Billion 24
Lannett Acquires Silarx Pharma for USD42 Million 26
Lannett Company Inc – Key Competitors 27
Lannett Company Inc – Key Employees 28
Lannett Company Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Aug 20, 2018: Lannett announces preliminary fiscal 2018 fourth-quarter and full-year financial results 30
May 07, 2018: Lannett Announces Fiscal 2018 Third-Quarter Financial Results 31
Feb 07, 2018: Lannett Announces Fiscal 2018 Second-Quarter Financial Results; Reports Record Revenues, Strong Earnings 32
Nov 06, 2017: Lannett Reports Solid Fiscal 2018 First-Quarter Financial Results, Significantly Increases Fiscal 2018 Guidance 33
Aug 23, 2017: Lannett Reports Fiscal 2017 Fourth-Quarter And Full-Year Financial Results, Provides Guidance For Fiscal 2018 34
Aug 08, 2017: Lannett Announces Preliminary Fiscal 2017 Fourth-Quarter And Full-Year Financial Results, Comments On Fiscal 2018 Outlook 35
May 02, 2017: Lannett Reports Fiscal 2017 Third-Quarter Financial Results 36
Feb 01, 2017: Lannett Reports Fiscal 2017 Second-Quarter Financial Results 37
Corporate Communications 38
Apr 30, 2018: Lannett Announces Changes To Board Of Directors 38
Apr 20, 2018: Lannett Names Maureen Cavanaugh Senior Vice President And Chief Commercial Operations Officer 39
Jan 18, 2018: Lannett Appoints Timothy C. Crew As Board Of Directors 40
Dec 21, 2017: Lannett Appoints Timothy C. Crew As CEO 41
Sep 25, 2017: Lannetts Board Of Directors Initiates CEO Search 42
Jul 17, 2017: Lannett Appoints Samuel H. Israel As General Counsel 43
Jun 20, 2017: Lannett Names Patrick G. LePore To Board of Directors 44
Legal and Regulatory 45
Nov 01, 2017: Lannett Comments On Amended Civil Complaint 45
Product News 46
Jul 23, 2018: Lannett Announces Multiple Product Launches 46
06/26/2017: Lannett Receives Approval For Additional Dosage Strengths Of Hydrocodone Bitartrate And Acetaminophen Tablets USP 47
Other Significant Developments 48
Jun 29, 2018: Lannett Announces Restructuring Plan Of Cody Laboratories Subsidiary 48
Mar 12, 2018: Lannett Adds New Revenue Streams, Announces Agreements With Three Strategic Alliance Partners 49
Mar 30, 2017: Lannett Voluntarily Pays Down Additional $25 Million Of Revolving Credit Facility 50
Feb 07, 2017: Lannett Announces Successful Completion Of ERP System Extraction 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List of Tables
Lannett Company Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lannett Company Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lannett Company Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Lannett Company Inc, Medical Devices Deals, 2012 to YTD 2018 11
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Lannett Acquires Portfolio of Generic Products from Endo International 13
Lannett to Acquire Estradiol Tablets and Selegiline Hydrochloride Capsules 14
Lannett Enters into Distribution Agreement with Aralez Pharma 15
Lannett to Form Partnership with YiChang HEC ChangJiang Pharmaceutical 16
Lannett Enters into Co-Marketing Agreement with Sunshine Lake 17
Panacea Biotec Enters Into R&D Agreement With Kremers Urban For Generic Drugs 18
Lannett Amends Licensing Agreement with Andor Pharma 19
Lannett Company Files Registration Statement to Raise Funds through Public Offering of Securities 20
Lannett Completes Public Offering Of Shares For US$76.5 Million 21
Lannett Files Shelf Registration Statement For Public Offering Of Securities For Up To US$64 Million 22
Lannett Company Plans to Sell Cody Laboratories 23
Lannett Acquires Kremers Urban Pharma for USD1.23 Billion 24
Lannett Acquires Silarx Pharma for USD42 Million 26
Lannett Company Inc, Key Competitors 27
Lannett Company Inc, Key Employees 28
Lannett Company Inc, Other Locations 29
Lannett Company Inc, Subsidiaries 29

List of Figures
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Lannett Company Inc, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Lannett Company Inc (LCI):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Brambles Limited (BXB):企業の財務・戦略的SWOT分析
    Brambles Limited (BXB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Exact Sciences Corp (EXAS):製品パイプライン分析
    Summary Exact Sciences Corp (Exact) is a molecular diagnostic company that focuses on the early detection and prevention of various cancers. The company’s flagship product, Cologuard test is a non-invasive stool-based deoxyribonucleic acid (DNA) screening product indicated for the early detection of …
  • Autoliv, Inc.:企業の戦略・SWOT・財務情報
    Autoliv, Inc. - Strategy, SWOT and Corporate Finance Report Summary Autoliv, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Gritstone Oncology Inc (GRTS):製薬・医療:M&Aディール及び事業提携情報
    Summary Gritstone Oncology Inc (Gritstone) develops and commercialize tumor-specific cancer immunotherapies. The company’s pipeline product portfolio comprises GRANITE-001, for solid tumors, including metastatic non-small cell lung cancer and gastroesophageal, bladder and colorectal cancers; and SLA …
  • Synaffix BV:製薬・医療:M&Aディール及び事業提携情報
    Summary Synaffix BV (Synaffix) is a biotechnology company that discovers and develops site-specific antibody-drug conjugates technology platforms. The company develops its products through its proprietary technology and GlycoConnect. It constructs homogenous and stable ADCs with the aid of a payload …
  • Neoleukin Therapeutics Inc (NLTX):企業の財務・戦略的SWOT分析
    Summary Neoleukin Therapeutics Inc (Neoleukin), formely Aquinox Pharmaceuticals Inc is a biopharmaceutical company develops next generation immunotherapies to treat immunological disorders. The company's lead drug candidate NL-201 is a combined IL-2 and IL-15 protein therapeutic used as an agonist i …
  • Xeltis AG:医療機器:M&Aディール及び事業提携情報
    Summary Xeltis AG (Xeltis) is a clinical-stage medical equipment company that harnesses advances in science to improve the treatment of heart valve related conditions. The company’s polymer-based technology platform, RestoreX, facilitates the natural restoration of heart valve through a process refe …
  • Essilor International Compagnie Generale d’Optique SA (EI):医療機器:M&Aディール及び事業提携情報
    Summary Essilor International Compagnie Generale d'Optique SA (Essilor) designs, manufactures and distributes ophthalmic lenses, sunwear, reading glasses and optics equipment. The company offers a range of corrective lenses for correcting visual disorders such as myopia, hypermetropia and astigmatis …
  • Sunstar Holding AG:企業の戦略・SWOT・財務分析
    Sunstar Holding AG - Strategy, SWOT and Corporate Finance Report Summary Sunstar Holding AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Checkpoint Surgical LLC:医療機器:M&Aディール及び事業提携情報
    Summary Checkpoint Surgical LLC (Checkpoint Surgical) is a medical device company that offers neuro-protective surgery equipment. The company offers neuro-protective devices including checkpoint stimulators and locators; and checkpoint head and neck systems. Its checkpoint stimulators and locators p …
  • Synthon Holdings BV:企業の戦略的SWOT分析
    Synthon Holdings BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Marathon Oil Corporation:企業の戦略・SWOT・財務分析
    Marathon Oil Corporation - Strategy, SWOT and Corporate Finance Report Summary Marathon Oil Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Handok Inc (002390)-製薬・医療分野:企業M&A・提携分析
    Summary Handok Inc (Handok), formerly known as Handok Pharmaceuticals Co Ltd, is a pharmaceutical and health care company which develops, manufactures and distributes healthcare solutions. The company develops and provides pharmaceutical products including prescription drugs, OTC drugs, medical devi …
  • AnGes Inc (4563):企業の財務・戦略的SWOT分析
    AnGes Inc (4563) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • FRONTEO, Inc. (2158):企業の財務・戦略的SWOT分析
    FRONTEO, Inc. (2158) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • De La Rue Plc (DLAR):企業の財務・戦略的SWOT分析
    De La Rue Plc (DLAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Pfizer Ltd India (PFIZER):企業の財務・戦略的SWOT分析
    Summary Pfizer Ltd India (Pfizer India), a subsidiary of Pfizer Inc, is a pharmaceutical company that develops medicines for brain disorders. The company’s products portfolio comprises of anti-allergics, anti-diabetics, anti-histamines, anti-infectives, anti-parasitics, drugs for cardiovascular and …
  • Lensar Inc-医療機器分野:企業M&A・提携分析
    Summary Lensar Inc (Lensar), a subsidiary of Alphaeon Corp is a medical device company that designs, develops and manufactures laser and advanced 3D imaging technology and devices for refractive cataract surgery. The company provides surgeon with superior femtosecond laser technology. It offers vari …
  • Caribbean Utilities Company, Ltd.:企業の発電所・SWOT分析2018
    Caribbean Utilities Company, Ltd. - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on …
  • Ornua Co-operative Ltd:企業の戦略・SWOT・財務分析
    Ornua Co-operative Ltd - Strategy, SWOT and Corporate Finance Report Summary Ornua Co-operative Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆